Article Per Year (5 Year)
p-Index From 2021 - 2026
0.23
P-Index
This Author published in this journals
All Journal Journal Pharmasci (Journal of Pharmacy and Science)
Syarofina Diniati
Universitas Kadiri
Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
The Impact of Polypharmacy on Blood Pressure Achievement in Hypertensive Patients with Complications: Pengaruh Polifarmasi terhadap Pencapaian Tekanan Darah pada Pasien Hipertensi dengan Komplikasi Elly Megasari; Syarofina Diniati; Arifani Siswidiasari; Tsamrotul Ilmi; Henni wati
Journal Pharmasci (Journal of Pharmacy and Science) Vol. 11 No. 2 (2026): Journal Pharmasci (Journal of Pharmacy and Science)
Publisher : Akademi Farmasi Surabaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.53342/pharmasci.v11i2.599

Abstract

Hypertension is a non-communicable disease and a major risk factor for cardiovascular disease. Polypharmacy, defined as the concurrent use of multiple medications, is commonly observed in hypertensive patients, particularly those with comorbidities. Although polypharmacy may improve therapeutic outcomes, it also increases the risk of drug interactions, adverse drug reactions, and poor medication adherence, which may affect blood pressure control. This study aimed to describe the pattern of polypharmacy and evaluate its association with blood pressure target achievement among hypertensive patients. An analytical observational study with a cross-sectional design was conducted using retrospective data collected from the medical records of 75 eligible hypertensive patients. The association between polypharmacy and blood pressure target achievement was analyzed using Spearman's Rank correlation test with a 95% confidence level. The results showed that the most frequently prescribed antihypertensive regimen was a two-drug combination (25%), while the most commonly used antihypertensive class was the Angiotensin Receptor Blocker (ARB), particularly candesartan. Most patients experienced mild polypharmacy (<5 medications) (64%), followed by severe polypharmacy (>5 medications) (21.3%), whereas 14.7% did not experience polypharmacy. Only 36% of patients achieved the target blood pressure, while 64% failed to reach the target. Spearman's Rank analysis demonstrated no significant association between polypharmacy and blood pressure target achievement (p = 0.135; r = -0.174). Although no significant relationship was identified, regular evaluation of polypharmacy remains essential to minimize drug interactions and optimize therapeutic outcomes in hypertensive patients.   
Co-Authors Arifani Siswidiasari Elly Megasari Henni Wati Tsamrotul Ilmi